The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies

The bioinformatics partnering deal trend analysis 2009 to 2014 are reviewed in this article.

Bioinformatics is the application of computer science and information technology to the field of biology and medicine.

The bioinformatics life science partnering deal trends 2007 to 2013 are reviewed in this article

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in September 2014.

Recent advances in biomarkers, pharmacogenomics, bioinformatics and companion diagnostics have raised opportunities in the emerging field of personalized medicine

This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in August 2013

Bristol-Myers Squibb (BMS) is a top pharmaceutical company discovery, development and commercialization of medicinal products worldwide

This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in February 2013

Is togetherness the latest drug? Will touchy feeliness be the answer to the pharmaceutical industry’s crisis of productivity?

Mega merger forms DaVita Healthcare Partners, Bigpharma join forces in search for new antibiotics, and Royalty Pharma raises significant funds for further royalty deals

Roche has agreed to acquire Dutalys and Bino Technologies in a end of year acquisition push

Intrexon Corporation has entered into an Exclusive Channel Collaboration with Sanofi Chimie to develop an enhanced production process for a specific family of its marketed Active Pharmaceutical Ingredients through Sanofi’s current manufacturing operations in France.

RaySearch Laboratories has entered biotech deals for its RayStation treatment planning system with Provision Center for Proton Therapy.

Merck Serono, a big pharma company announced the creation of Quartz Bio, the second spin-off company resulting from its Entrepreneur Partnership Program launched in April 2012.

Astellas Pharma has extended and renewed its license to the GVK BIO SAR Databases (GOSTAR).

Roche says that it will work with the University of Geneva, Geneva University Hospitals and the Swiss Institute of Bioinformatics in the translational research arena–